Welcome to our dedicated page for Vertex Pharmaceuticals news (Ticker: VRTX), a resource for investors and traders seeking the latest updates and insights on Vertex Pharmaceuticals stock.
Vertex Pharmaceuticals develops biotechnology medicines for serious diseases and conditions, with commercial franchises in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain. Company news commonly covers CFTR modulators including ALYFTREK and TRIKAFTA, the CRISPR/Cas9 gene-edited therapy CASGEVY, and JOURNAVX, an oral non-opioid pain signal inhibitor.
Updates also track financial results, regulatory approvals and label expansions, reimbursement and patient-access agreements, clinical data presentations, and pipeline programs in kidney disease, neuropathic pain, type 1 diabetes, generalized myasthenia gravis and myotonic dystrophy type 1. Vertex disclosures frequently connect revenue trends with progress across approved products and investigational programs such as povetacicept for IgA nephropathy.
Vertex Pharmaceuticals (NASDAQ: VRTX) has partnered with basketball Hall-of-Famer Alonzo Mourning to launch the "Power Forward" initiative. This educational campaign aims to raise awareness about APOL1-mediated kidney disease (AMKD), emphasizing the significance of early diagnosis and genetic testing. AMKD affects approximately 100,000 individuals in the U.S. and is genetically driven, particularly impacting those of sub-Saharan African ancestry. The initiative offers resources to help at-risk individuals discuss kidney health with healthcare providers.
Vertex Pharmaceuticals (NASDAQ: VRTX) reports promising long-term data on TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor), showcased at the North American Cystic Fibrosis Conference. The ongoing 192-week study shows sustained improvements in lung function and respiratory symptoms among patients with at least one F508del allele. In children aged 2-5, TRIKAFTA improved lung function and was generally well-tolerated. Vertex plans to submit regulatory applications for this age group. The latest findings reinforce TRIKAFTA's critical role in CF treatment.
Vertex Pharmaceuticals reported Q3 2022 product revenues of $2.33 billion, marking an 18% increase from Q3 2021. The company raised its full-year 2022 product revenue guidance to $8.8 billion to $8.9 billion, driven by strong uptake of TRIKAFTA/KAFTRIO. Net income increased by 9% to $931 million, with a diluted EPS of $3.59. Vertex continues to advance its clinical pipeline, including exa-cel for Sickle Cell Disease and VX-548 for acute pain, while increasing R&D investments.
Vertex Pharmaceuticals (NASDAQ: VRTX) will report its Q3 2022 financial results on October 27, 2022, after market close. A conference call is scheduled for 4:30 p.m. ET to discuss these results, accessible via phone and live webcast on Vertex's website.
Vertex is a leader in biotechnology, focusing on transformative medicines for serious diseases, particularly cystic fibrosis, and has a robust pipeline addressing other conditions like sickle cell disease and type 1 diabetes. The company is recognized as a top employer in the industry.
Vertex Pharmaceuticals (NASDAQ: VRTX) has initiated a first-in-human trial for VX-634, a new AAT corrector for alpha-1 antitrypsin deficiency (AATD). The FDA has approved the IND application for VX-634, marking a significant advancement in the company's AATD program. Alongside this, Vertex plans to launch a 48-week Phase 2 study of VX-864 to evaluate its long-term efficacy in reducing liver polymer levels and increasing functional AAT in plasma. The company will also introduce additional AAT correctors starting in 2023.
Vertex Pharmaceuticals and CRISPR Therapeutics have announced a rolling review of exa-cel by the U.S. FDA for treating sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), with submission starting in November 2022 and completion expected by Q1 2023. Submissions to the EMA and MHRA are also on track for Q4 2022. Exa-cel received multiple designations, including Fast Track and Orphan Drug status. The therapy aims to edit patients' stem cells for improved disease outcomes.
Vertex Pharmaceuticals (NASDAQ: VRTX) appointed Jonathan Biller as Chief Legal Officer effective September 19, 2022. Biller joins from Agios, where he held multiple executive roles, including Chief Financial Officer. Dr. Reshma Kewalramani, CEO, expressed excitement about Biller's depth of legal and industry experience, expecting him to support Vertex’s growth in cystic fibrosis and other disease treatments. Vertex continues to develop innovative therapies for serious diseases, including sickle cell disease and type 1 diabetes.
Vertex Pharmaceuticals has received FDA approval for the expanded use of ORKAMBI (lumacaftor/ivacaftor) to treat children aged 12 to under 24 months with cystic fibrosis who possess two copies of the F508del mutation. This represents the first time a treatment is available for this age group suffering from the underlying disease. This approval is founded on a recent Phase 3 study showing ORKAMBI's safety and potential to modify the disease's progression. ORKAMBI was first approved in 2015 and is currently available in over 30 countries.
Vertex Pharmaceuticals (NASDAQ: VRTX) announced participation in a fireside chat at the Wells Fargo Healthcare Conference on September 9, 2022, at 11:00 a.m. ET.
A live webcast of the event will be available on the company's website under the 'Investors' section. Vertex is a biotechnology company focusing on transformative medicines for serious diseases, notably cystic fibrosis, and has a strong pipeline addressing various genetic and chronic conditions.
Vertex Pharmaceuticals reported strong Q2 2022 results with product revenues of $2.20 billion, marking a 22% increase year-over-year. The company raised its full-year revenue guidance to $8.6 to $8.8 billion. Key drivers include the strong adoption of TRIKAFTA/KAFTRIO, particularly in the U.S., and advancements in multiple clinical programs for diseases like sickle cell and type 1 diabetes. Net income rose significantly to $810 million, or $3.13 per diluted share. Vertex's pipeline boasts late-stage clinical developments, promising a substantial growth trajectory.